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Introduction
Patients with advanced endometrial and cervical cancers have
limited therapeutic options and the prognosis is poor
Median overall survival following 1st line therapy for advanced
disease is……
Early phase trials may be a suitable option for patients with good
performance status
Increasingly, molecular characterisation guides pt selection for
early phase trials
We sought to determine the outcome of endometrial and cervical
cancer patients treated in a phase 1 unit and examined the role of
molecular selection to inform therapeutic decision making
Methods
 Medical records of all patients with an endometrial, cervical,
vaginal or vulva malignancy treated within an early phase trial
between 2010 and 2016 were reviewed
 Data comprising patient and tumor characteristics, prior
treatment, trial therapy and outcome were analysed
 Next Generation Sequencing (NGS) profiling was performed,
where available using a 22 gene amplicon-based panel (Life
Technologies Colon & Lung V2)
 Detected variants are reviewed at a local genomics review board
to assess potential actionability prior to considering therapy
Results
43 patients were identified with a diagnosis of endometrial cancer
(EC, 23) or cervical/vulva cancer (CVC, 20) and treated on 46
allocated trials
Median age 59 years (range 20-80)
Median prior therapies 1 (0-3)
21 patients (46%) ≥ 2 prior therapies for advanced disease
Histological subtype N 
Endometrial High grade serous 8
Clear cell 1
Carcinosarcoma 4
Endometrioid 8
Other 5
Histological subtype N 
Cervix/Vulva Squamous 13
Adenocarcinoma 5
Clear cell 2
Neuroendocrine 1
An actionable mutation identified in 55% (11/20), including KRAS
(5 patients), PIK3CA (6 patients) and EGFR, PTEN and AKT (1
each)
Phase 1 Trial Enrolment
Pts were allocated in order of priority as follows:
 (1) a trial selected on the basis of NGS (‘genomic’, 15%),
 (2) a ‘tumour specific’ cohort within an early phase trial (59%)
 (3) a ‘generic’ study (26%)
Genotype directed trials included PI3K, FGFR, mTOR and MEK
inhibitor studies
Trials with tumour specific cohorts included novel chemotherapy
agents, antibody-drug conjugates and single and combination
immunotherapy studies
Generic studies included novel chemotherapy, ATR inhibitor and
vascular disrupting agents
Outcome: Response Rates
 41 patients (89%) are evaluable for response
The overall response rate (ORR, complete and partial responses
as defined by RECIST) was 22% with a clinical benefit (ORR and
stable disease) rate of 63%
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Figure 1: Response Evaluation
Outcome: Treatment Duration
Duration of study treatment was significantly longer for patients
treated within tumour specific cohorts (30 weeks) than either
genomic or generic studies (9 and 8 weeks respectively, p=0.03
Mantel-Cox)
Outcome: Overall Survival
At the time of analysis, 24 (47%) patients remain alive
Median overall survival:
 36 weeks (4-141) for all patients
 35 weeks (4-140) for EC and 60 weeks (6-141) for CVC
patients
Overall survival was longer for patients treated within tumour
specific cohorts (66 weeks) than either genomic (31 weeks) or
generic studies (37 weeks) although this did not reach significance
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Conclusions
Figure 3: 
Overall Survival
Figure 2:
Treatment
duration
Next Generation Sequencing (NGS)
NGS was successfully performed in 20 patients (47%)
 90% (18/20) of patients had a detected variant in ≥ 1 gene
Outcome: Treatment Duration
At the time of analysis, 13 (30%) patients remained on study
Median duration on study drug:
 12 weeks (3-87) for all patients
 11 weeks (3-87) for EC and 12 weeks (5-87) for CVC patients
NGS
Early phase trials represent a good option for patients with
advanced EC and CVC with meaningful clinical benefit observed
Encouraging response rates and duration of responses were
observed in these patients with limited treatment options, including
patients with difficult to treat subtypes such as high grade serous
and carcinosarcoma EC and clear cell CVC
